COMMUNICATION:
Bik and Bak Induce Apoptosis Downstream of CrmA but Upstream of Inhibitor of Apoptosis*

(Received for publication, January 30, 1997, and in revised form, February 18, 1997)

Kim Orth and Vishva M. Dixit Dagger

From the Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Recent studies have identified a number of cell death pathway components. In this study, we describe the role that two such components, Bik and Bak, play in initiating the apoptotic program. These Bcl-2 family members engage the death pathway downstream of the block imposed by the serpin CrmA, but upstream of the block initiated by cellular inhibitors of apoptosis, which are a family of molecules characterized by a conserved baculovirus inhibitor of apoptosis repeat motif. Distal death pathway components activated by Bik and Bak are similar to those activated by the CD-95 (Fas/Apo1) and tumor necrosis factor death receptors.


INTRODUCTION

Apoptosis or programmed cell death plays a critical role in the survival of multicellular organisms. Unchecked, it can contribute to a number of degenerative conditions such as Alzheimer's disease (1, 2). Conversely, excessive inhibition of cell death can lead to the accumulation of abnormal cells that may become transformed or contribute to autoimmune disease (3). Therefore, preserving the balance between pro- and anti-apoptotic influences is essential for maintaining tissue homeostasis (4).

Genetic studies in Caenorhabditis elegans have contributed much to the understanding of key components of the cell death machinery by the identification of an inhibitor of apoptosis, ced-9, and two inducers of apoptosis, ced-3 and ced-4 (5). The ced-9 gene is homologous to the human bcl-2 gene, which is overexpressed in follicular lymphomas and contributes to a heightened state of resistance to cell death induced by a variety of agents including glucocorticoids and irradiation (6-9). Although the mammalian homologue of ced-4 has yet to be identified, CED-3 is homologous to a family of interleukin-1-converting enzyme-like proteases (ICE)1 recently renamed caspases (10, 11). Caspases are cysteine proteases that cleave substrates following aspartate residues and when overexpressed can induce apoptosis (12, 13). In addition, caspases are converted from an inactive zymogen form to a cleaved active dimeric species upon receipt of a death signal (14, 15).

Although the components identified in C. elegans have revealed some of the essential mammalian counterparts involved in apoptosis, additional complexity exists in mammalian systems. A number of receptors involved in immune function that contain death domains, including CD-95, tumor necrosis factor receptor-1 (TNFR1 or p55), and DR3/WSL-1, can engage the death pathway by using adapter molecules such as FADD/MORT1 to directly recruit a proximal caspase (caspase-8/FLICE/MACH) (16-25). Additionally, while there is only one ced-9 gene in C. elegans, there are a number of Bcl-2 homologues in mammals that can either suppress (Bcl-x) (26) or activate (Bax, Bik, Bak) (27-31) the apoptotic program. Superimposed on this are viral inhibitors of cell death that attenuate the pathway allowing for increased replication of viral progeny in infected host cells. The pox virus-encoded serpin, CrmA, preferentially inhibits proximal components of the ICE/CED-3 protease cascade, including caspase-8 (32, 33). In contrast, the baculoviral encoded gene product p35 interrupts the death pathway by inhibiting a broad spectrum of caspases (34, 35). Additional baculoviral gene products that inhibit apoptosis are the IAP molecules (Cp-IAP and Op-IAP) that are characterized by protein repeat (BIR) domains (36). While the exact mode of action of these inhibitors is unclear, homologues in Drosophila and humans have been identified (37-41). Remarkably, deficiency of one of the human IAP genes (NIAP) may contribute to the excessive neuronal apoptosis that characterizes spinal muscular atrophy (42, 43).

To gain a better understanding of how these different modulators and effectors of apoptosis might function, we investigated the activities of two activators of apoptosis, Bik and Bak, with respect to various inhibitors of the cell death program. Herein, we show that the activation of apoptosis by Bik and Bak occurs downstream of the CrmA block. However, a broad spectrum peptide inhibitor of the caspase family, z-VAD-fmk, attenuated cell death induced by Bik or Bak, implying a downstream effector role for caspases. Confirming this is the finding that caspase-7, a distal caspase, is processed to its active form upon induction of cell death by Bik or Bak. Surprisingly, the mammalian counterparts to the baculoviral IAPs (cIAP1 and cIAP2) inhibited Bik- and Bak-induced apoptosis. This allows for the derivation of a model that tentatively positions the aforementioned components in the apoptotic program.


MATERIALS AND METHODS

Cell Lines

MCF7, a human breast carcinoma cell line transfected with either vector (Neo-vector) or a CrmA expression construct (Neo-CrmA) (33) was maintained in RPMI containing 10% heat-inactivated fetal bovine serum. The HA-Bik and HA-Bak constructs were generously provided by G. Chinnadurai. The myc-IAP1 and myc-IAP2 constructs were generously provided by D. V. Goeddel. The p55 TNF receptor construct was described previously in Ref. 19.

Death Assays

These were performed essentially as described previously (44). Briefly, parental, Neo-vector or Neo-CrmA cells were plated on a six-well tissue culture dish (2 × 105 cells/well) and transiently transfected with 100 ng of the reporter plasmid pCMV-beta -galactosidase plus 0.2 µg of the test plasmid. Inhibition assays included 0.8 µg of the inhibitor test plasmid. Five hours following transfection, 1 ml of complete medium (in the presence or absence of 40 µM z-VAD-fmk) was added. Nonapoptotic or apoptotic cells were detected by staining with 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside as described previously (44). Percent apoptotic cells represents the mean value from two or more experiments (mean ± S.D.).

Immunoblotting Analysis

This was performed essentially as described previously (45). Transiently transfected 293 cells (~2 × 106 cells) were lysed in Buffer A (0.1% Nonidet P-40, 50 mM Hepes, pH 7.6, 50 mM KCl, 10 mM EGTA, 2 mM MgCl, 1 mM dithiothreitol plus protease inhibitors), clarified by centrifugation, and the supernatant resolved by SDS-polyacrylamide gel electrophoresis. After transfer to nitrocellulose, the filter was incubated with a 1:1000 dilution of the caspase-7 antibody followed by incubation with a 1:10,000 dilution of secondary goat anti-rabbit horseradish peroxidase conjugate (Amersham Corp.). Bound antibody was visualized using the ECL kit (Amersham) as per manufacturer's instructions. Poly(ADP-ribose) polymerase (PARP) was detected in urea/SDS-solubilized nuclei by immunoblotting as described previously (46).


RESULTS AND DISCUSSION

Bik and Bak Activate Programmed Cell Death Downstream of the CrmA Block

CrmA is a virally encoded serpin that inhibits both CD-95 and TNF-induced cell death (33). It apparently functions at the apex of these receptor-initiated cell death pathways based on its ability to block the activation of a number of downstream caspases, including caspase-3 (YAMA, CPP32, apopain), caspase-6 (Mch2), and caspase-7 (ICE-LAP3, Mch3, CMH-1) (20, 24, 33, 47, 48). Therefore, the protease(s) that CrmA inhibits must be upstream of these distal caspases. Additionally, staurosporine can by-pass the proximal CrmA block and induce activation of these same distal caspases (47, 48). Finally, CrmA is a relatively weak inhibitor of the distal caspases (caspase-3, caspase-6, and caspase-7), whereas it is a potent inhibitor of caspase-8, which functions at the apex of the cascade (32, 49). Using the previously characterized MCF7 vector or CrmA stable transfectants, we investigated whether the proapoptotic members of the Bcl-2 family, Bik and Bak, could by-pass the upstream CrmA block.

As observed previously, TNF induced apoptosis in the vector control cell line, whereas the CrmA cell line was protected (Fig. 1) (33). The vector control cell line transfected with Bik or Bak underwent apoptosis. However, the CrmA-expressing cell line also underwent apoptosis with similar kinetics. Identical results were observed when CrmA and Bik or Bak were transiently cotransfected into the parental MCF7 cell line, implying that the result was not attributable to clonal variation (data not shown). The gross morphology of the apoptotic cells induced to die by either overexpression of Bik or Bak or treatment with TNF was indistinguishable. Therefore, although Bik and Bak must initially activate a distinct pathway from that engaged by CD-95 or TNF (as revealed by CrmA sensitivity), downstream of CrmA the pathways are likely to be similar.


Fig. 1. CrmA inhibits TNF-induced cell death, but not Bik- or Bak-induced cell death. The Neo-vector or Neo-CrmA cell line was transiently transfected with a reporter gene (beta -galactosidase) followed by treatment with human TNF (50 ng/ml). Alternatively, these lines were transiently transfected with the reporter gene and expression constructs encoding either Bik or Bak.
[View Larger Version of this Image (65K GIF file)]


Bik and Bak Activate Caspases to Induce Cell Death

In vivo, caspases are potently inhibited by the cell permeable, broad spectrum peptide inhibitor z-VAD-fmk (50, 51). This peptide inhibitor abrogates both CD-95- and TNF-induced cell death (Fig. 2A) and attenuates a number of other forms of death, including glucocorticoid-induced death (8, 9). Likewise, Bik- and Bak-induced cell death was inhibited by z-VAD-fmk (Fig. 2A), consistent with death being mediated by caspase activation.


Fig. 2. Bik and Bak induce the activation of caspases. A, MCF7 cells were transiently transfected with the beta -galactosidase reporter gene followed by treatment with human TNF (50 ng/ml) in the presence or absence of 20 µM z-VAD-fmk. Alternatively, MCF7 cells were transiently transfected with the reporter gene and either Bik or Bak expression constructs in the presence or absence of 20 µM z-VAD-fmk. B, activation of caspase-7. The zymogen form of caspase-7 is observed in mock-transfected 293 cells, whereas the active cleaved form is detected in 293 cells transiently transfected with the p55 TNF receptor (second lane). Cleaved forms include a processing intermediate form (~30 kDa) and the large catalytic subunit (~20 kDa). Similarly, 293 cells transiently transfected with either Bik (third lane) or Bak (fourth lane) generate the processed form of caspase-7. C, PARP cleavage: Intact PARP is observed in mock treated 293 cells whereas the signature apoptotic form is observed in 293 cells transiently transfected with the p55 TNF receptor (second lane), Bik (third lane), or Bak (fourth lane).
[View Larger Version of this Image (33K GIF file)]


To confirm this, the activation of one of the distal caspases, caspase-7, was examined. The caspases are found as single polypeptide zymogens in live cells, whereas upon receipt of a death signal (such as activation of CD-95 or TNF receptors or exposure to staurosporine) these proteases are processed into an active dimeric species (45, 47, 48). As shown in Fig. 2B, in mock-transfected cells (first lane) caspase 7 is present in its zymogen form, whereas in cells overexpressing the cytotoxic p55 TNF receptor (second lane) this caspase is converted to the active processed form as evidenced by the appearance of the large catalytic subunit (~20 kDa). Since Bik or Bak overexpression also resulted in the conversation of caspase-7 to its active form (Fig. 2B, third and fourth lanes, respectively), these proapoptotic Bcl-2 homologues must promote the activation of downstream caspases.

Finally, we analyzed the state of the endogenous apoptotic substrate, PARP (46). In nonapoptotic cells PARP is observed in the uncleaved form (116 kDa), whereas in apoptotic cells PARP is characteristically cleaved to an indicator apoptotic fragment (85 kDa) by a variety of active caspases (Fig. 2C, first and second lanes, respectively). As shown in Fig. 2C, cells transiently transfected with Bik (third lane) or Bak (fourth lane) contained this signature apoptotic PARP fragment that presumably was the result of cleavage by an activated endogenous caspase. This provides additional confirmation that Bik and Bak can by-pass the CrmA block and functionally activate downstream caspases.

IAPs Inhibit Bik- and Bak-induced Cell Death

By contrast to CrmA, the mammalian counterparts of the baculoviral IAP genes (cIAP1 and cIAP2) inhibited both Bik- and Bak-induced apoptosis. Cells transiently cotransfected with Bik or Bak and either cIAP1 or cIAP2 (singly or together) did not undergo apoptosis (Fig. 3). Since no physical association between Bik or Bak and the cIAPs was observed (data not shown), it is likely that the effect involves an intermediary molecule(s). Regardless, Bik and Bak engage the death pathway upstream of the IAP block.


Fig. 3. Bik- and Bak-induced cell death is inhibited by IAPs. Apoptosis was triggered when MCF7 cells were transiently transfected with either Bik or Bak. By contrast, when MCF7 cells were transiently transfected with either Bik or Bik in combination with cIAP1 or cIAP2 (together or separately), cell death was attenuated.
[View Larger Version of this Image (38K GIF file)]


Molecular Ordering of Bik and Bak in the Apoptotic Pathway

Our results are consistent with a model whereby Bik and Bak trigger apoptosis by activation of caspases distal to the CrmA block but upstream of the IAPs. Our studies, however, do not address the question of whether Bik and Bak act by directly engaging the death machinery or by simply inhibiting an inhibitor of apoptosis such as Bcl-2. Finally, Bik and Bak were shown to promote the activation of distal caspases similar to those utilized by the CD-95 and TNF death pathways (Fig. 4).


Fig. 4. Relative order of death pathway activators and inhibitors. At the apex of the cascade are the receptor (CD-95 and TNF)-initiated death signals that are susceptible to CrmA inhibition. Downstream of this block, other Bcl-2-inhibitable death stimuli can enter the death pathway. Bik and Bak may inhibit Bcl-2 directly to release an unidentified cytotoxic factor. Alternatively, Bik and Bak may activate the pathway directly. Regardless IAPs function downstream of Bik and Bak. Activation of distal caspases results in cell death.
[View Larger Version of this Image (13K GIF file)]



FOOTNOTES

*   This work was supported by National Institutes of Health Grants CA64803 and CA68769.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: University of Michigan Medical School, Dept. of Pathology, 1301 Catherine St., Box 0602, Ann Arbor, MI 48109. Tel.: 313-647-2921; Fax: 313-764-4308; E-mail: vmdixit{at}umich.edu.
1   The abbreviations used are: ICE, interleukin-1-converting enzyme-like protease(s); PARP, poly(ADP-ribose) polymerase; IAP, inhibitor of apoptosis; TNF, tumor necrosis factor; z-VAD-fmk, z-Val-Ala-Asp-fluoromethyl ketone.

ACKNOWLEDGEMENTS

We are grateful to G. Chinnadurai and D. V. Goeddel for expression constructs. For technical help and helpful discussions, we thank C. Vincenz, E. Humke, K. O'Rourke, and D. R. Beidler. A special thanks to Ian Jones for his assistance with figures. K. O. appreciates the helpful advice from S. J. Orth.


REFERENCES

  1. Vito, P., Wolozin, B., Ganjei, J. K., Iwasaki, K., Lacana, E., and D'Amamio, L. (1996) J. Biol. Chem. 271, 31025-31028 [Abstract/Free Full Text]
  2. Vito, P., Lacana, E., and D'Adamio, L. (1996) Science 271, 521-525 [Abstract]
  3. Thompson, C. B. (1995) Science 267, 1456-1462 [Medline] [Order article via Infotrieve]
  4. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Br. J. Cancer 26, 239-257 [Medline] [Order article via Infotrieve]
  5. Horvitz, H. R., Shaham, S., and Hengartner, M. O. (1994) Cold Spring Harbor Symp. Quant. Biol. 59, 377-386 [Medline] [Order article via Infotrieve]
  6. Alnemri, E. S., Fernandes, T. F., Haldar, S., Croce, C. M., and Litwack, G. (1992) Cancer Res. 52, 491-495 [Abstract]
  7. Hengartner, M. O., and Horvitz, H. R. (1994) Cell 76, 665-676 [Medline] [Order article via Infotrieve]
  8. White, E. (1996) Genes Dev. 10, 1-15 [CrossRef][Medline] [Order article via Infotrieve]
  9. Raff, M. C. (1992) Nature 356, 397-400 [CrossRef][Medline] [Order article via Infotrieve]
  10. Cerretti, D. P., Kozlosky, C. J., Mosley, B., Nelson, N., Ness, K. V., Greenstreet, T. A., March, C. J., Kronheim, S. R., Druck, T., Cannizzaro, L. A., Huebner, K., and Black, R. A. (1992) Science 256, 97-100 [Medline] [Order article via Infotrieve]
  11. Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 356, 768-774 [CrossRef][Medline] [Order article via Infotrieve]
  12. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., and Yuan, J. (1993) Cell 75, 653-660 [Medline] [Order article via Infotrieve]
  13. Chinnaiyan, A., and Dixit, V. M. (1996) Curr. Biol. 6, 555-562 [Medline] [Order article via Infotrieve]
  14. Kumar, S., and Harvey, N. L. (1995) FEBS Lett. 375, 169-173 [CrossRef][Medline] [Order article via Infotrieve]
  15. Martin, S. J., and Green, D. R. (1995) Cell 82, 349-352 [Medline] [Order article via Infotrieve]
  16. Itoh, N., and Nagata, S. (1993) J. Biol. Chem. 268, 10932-10937 [Abstract/Free Full Text]
  17. Tartaglia, L. A., Rothe, M., Hu, Y. F., and Goeddel, D. V. (1993) Cell 73, 213-216 [Medline] [Order article via Infotrieve]
  18. Nagata, S., and Golstein, P. (1995) Science 267, 1449-1456 [Medline] [Order article via Infotrieve]
  19. Chinnaiyan, A. M., O'Rourke, K., Yu, G. L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., Ni, J., and Dixit, V. M. (1996) Science 274, 990-992 [Abstract/Free Full Text]
  20. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81, 505-512 [Medline] [Order article via Infotrieve]
  21. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995) J. Biol. Chem. 270, 7795-7798 [Abstract/Free Full Text]
  22. Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) EMBO J. 14, 5579-5588 [Abstract]
  23. Boldin, M. P., Goncharo, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815 [Medline] [Order article via Infotrieve]
  24. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827 [Medline] [Order article via Infotrieve]
  25. Kitson, J., Raven, T., Jiang, Y.-P., Goeddel, D. V., Giles, K. M., Pun, K.-T., Grinham, C. J., Brown, R., and Farrow, S. N. (1996) Nature 384, 372-375 [CrossRef][Medline] [Order article via Infotrieve]
  26. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. (1993) Cell 74, 597-608 [Medline] [Order article via Infotrieve]
  27. Oltavai, Z. N., Millian, C. L., and Korsmeyer, S. J. (1993) Cell 74, 609-619 [Medline] [Order article via Infotrieve]
  28. Boyd, J. M., Gallo, G. J., Elangovan, B., Houghton, A. B., Malstrom, S., Avery, B. J., Ebb, R. G., Subramanian, T., Chittenden, T., Lutz, R. J., and Chinnadurai, G. (1995) Oncogene 11, 1921-1927 [Medline] [Order article via Infotrieve]
  29. Kiefer, M. C., Brauer, M. J., Powers, V. C., Wu, J. J., Umansky, S. R., Tomei, L. D., and Barr, P. J. (1995) Nature 374, 736-739 [CrossRef][Medline] [Order article via Infotrieve]
  30. Farrow, S. N., White, J. H., Martinou, I., Raven, T., Pun, K. T., Grinham, C. J., Martinou, J. C., and Brown, R. (1995) Nature 374, 731-733 [CrossRef][Medline] [Order article via Infotrieve]
  31. Chittenden, T., Harrington, E. A., O'Connor, R., Flemington, C., Lutz, R. J., Evan, G. I., and Guild, B. C. (1995) Nature 374, 733-736 [CrossRef][Medline] [Order article via Infotrieve]
  32. Muzio, M., Salvesen, G. S., and Dixit, V. M. (1997) J. Biol. Chem. 272, 2952-2956 [Abstract/Free Full Text]
  33. Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260 [Abstract/Free Full Text]
  34. Beidler, D. R., Tewari, M. T., Friesen, P. D., Poirier, G., and Dixit, V. M. (1995) J. Biol. Chem. 270, 16526-16528 [Abstract/Free Full Text]
  35. Bump, N. J., Hackett, M., Huginin, M., Sheshagiri, S., Brady, K., Chen, P., Ferenz, C., Franklin, S., Ghayur, T., Li, P., Licari, P., Mankovich, J., Shi, L., Greenburg, A. H., Miller, L. K., and Wong, W. W. (1995) Science 269, 1885-1888 [Medline] [Order article via Infotrieve]
  36. Clem, R. J., and Miller, L. K. (1994) Mol. Cell. Biol. 14, 5212-5222 [Abstract]
  37. Duckett, C. S., Nava, V. E., Gedrich, R. W., Clem, R. J., Van Dongen, J. L., Gilfillan, M. C., Shiels, H., Hardwick, J. M., and Thompson, C. B. (1996) EMBO J. 15, 2685-2694 [Abstract]
  38. Hay, B. A., Wassarman, D. A., and Rubin, G. M. (1995) Cell 83, 1253-1262 [Medline] [Order article via Infotrieve]
  39. Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., Cherton-Horvat, G., Farahani, R., McLean, M., Ikeda, J., Mackenzie, A., and Korneluk, R. G. (1996) Nature 379, 349-352 [CrossRef][Medline] [Order article via Infotrieve]
  40. Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M., and Goeddel, D. V. (1995) Cell 83, 1243-1252 [Medline] [Order article via Infotrieve]
  41. Uren, A. G., Pakusch, M., Hawkins, C. J., Puls, K. L., and Vaux, D. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4974-4978 [Abstract/Free Full Text]
  42. Roy, N., Mahadevan, M. S., McLean, M., Shutler, G., Yaraghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C., Kang, X., Salik, M., Aubry, H., Tamai, K., Guan, X., Ioannou, P., Crawford, T. O., de Jong, P. J., Surh, L., Ikeda, J.-E, Korneluk, R. G., and MacKenzie, A. (1995) Cell 80, 167-178 [Medline] [Order article via Infotrieve]
  43. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Le Paslier, D., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A., and Melki, J. (1995) Cell 80, 155-165 [Medline] [Order article via Infotrieve]
  44. Duan, H., Orth, K., Chinnaiyan, A. M., Poirier, G. G., Froelich, C. J., He, W. W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16720-16724 [Abstract/Free Full Text]
  45. Duan, H., Chinnaiyan, A. M., Hudson, P. L., Wing, J. P., He, W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 1621-1625 [Abstract/Free Full Text]
  46. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) Cell 81, 801-809 [Medline] [Order article via Infotrieve]
  47. Orth, K., Chinnaiyan, A. M., Garg, M., Froelich, C. J., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16443-16446 [Abstract/Free Full Text]
  48. Chinnaiyan, A. M., Orth, K., O'Rourke, K., Duan, H., Poirier, G. G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4573-4576 [Abstract/Free Full Text]
  49. Zhou, Q., Snipas, S., Orth, K., Muzio, M., Dixit, V. M., and Salvesen, G. (1997) J. Biol. Chem. 272, 7797-7800 [Abstract/Free Full Text]
  50. Fearnhead, H. O., Dinsdale, D., and Cohen, G. M. (1995) FEBS Lett. 375, 283-288 [CrossRef][Medline] [Order article via Infotrieve]
  51. Pronk, G. J., Ramer, K., Amiri, P., and Williams, L. T. (1996) Science 271, 808-810 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.